BCRX · Insider Trading
BioCryst Pharmaceuticals Inc
Every open-market purchase and sale reported by BCRX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-02 | Steven Frank | Director | A | +1,288 | +$12.49K |
| 2026-09-02 | Vincent Milano | Director | A | +1,159 | +$11.24K |
| 2026-09-02 | Jill C. Milne | Director | A | +1,288 | +$12.49K |
| 2026-09-02 | Amy E McKee | Director | A | +644 | +$6.25K |
| 2026-09-02 | Jon P Stonehouse | Director | A | +644 | +$6.25K |
| 2026-06-15 | Theresa Heggie | Director | A | +15,294 | — |
| 2026-06-15 | Vincent Milano | Director | A | +15,294 | — |
| 2026-06-15 | Jill C. Milne | Director | A | +15,294 | — |
| 2026-06-15 | Machelle Sanders | Director | A | +15,294 | — |
| 2026-06-15 | Steven K Galson | Director | A | +15,294 | — |
| 2026-06-15 | Jon P Stonehouse | Director | A | +15,294 | — |
| 2026-06-15 | Amy E McKee | Director | A | +15,294 | — |
| 2026-06-15 | Steven Frank | Director | A | +15,294 | — |
| 2026-06-15 | Alan G Levin | Director | A | +15,294 | — |
| 2026-06-02 | Jon P Stonehouse | Director | A | +631 | +$5.62K |
| 2026-06-02 | Steven Frank | Director | A | +1,262 | +$11.24K |
| 2026-06-02 | Vincent Milano | Director | A | +1,122 | +$10.00K |
| 2026-06-02 | Jill C. Milne | Director | A | +1,262 | +$11.24K |
| 2026-06-02 | Amy E McKee | Director | A | +631 | +$5.62K |
| 2026-05-19 | Amy E McKee | Director | Sell | −11,180 | −$100.28K |
| 2026-05-15 | Alane P Barnes | Chief Legal Officer | MIXED | — | −$281.25K |
| 2026-04-07 | Sandeep Menon | Chief R&D Officer | A | +205,150 | — |
| 2026-03-24 | Theresa Heggie | Director | MIXED | — | −$190.24K |
| 2026-03-18 | Alane P Barnes | Chief Legal Officer | MIXED | — | −$546.00K |
| 2026-03-03 | Vincent Milano | Director | A | +848 | +$7.42K |
| 2026-03-03 | Jill C. Milne | Director | A | +528 | +$4.62K |
| 2026-03-03 | Amy E McKee | Director | A | +642 | +$5.62K |
| 2026-03-03 | Steven Frank | Director | A | +1,285 | +$11.24K |
| 2026-03-03 | Jon P Stonehouse | Director | MIXED | +421 | −$1.65M |
| 2026-01-27 | Jill C. Milne | Director | A | +14,854 | — |
| 2025-12-23 | Jon P Stonehouse | Chief Executive Officer | F | −61,793 | −$457.89K |
| 2025-12-23 | Charles K Gayer | President and CCO | MIXED | +62,756 | +$286.85K |
| 2025-12-23 | Alane P Barnes | Chief Legal Officer | MIXED | −38,675 | −$291.81K |
| 2025-12-19 | Charles K Gayer | President and CCO | A | +471,000 | — |
| 2025-12-19 | Jon P Stonehouse | Chief Executive Officer | G | — | — |
| 2025-12-19 | Alane P Barnes | Chief Legal Officer | A | +121,700 | — |
| 2025-12-19 | Babar Ghias | Chief Financial Officer | A | +121,700 | — |
| 2025-12-16 | Alane P Barnes | Chief Legal Officer | MIXED | −29,750 | −$226.90K |
| 2025-12-16 | Jon P Stonehouse | Chief Executive Officer | F | −27,368 | −$207.18K |
| 2025-12-16 | Charles K Gayer | President and CCO | F | −8,181 | −$61.93K |
| 2025-12-03 | Alane P Barnes | Chief Legal Officer | MIXED | −70,676 | −$871.93K |
| 2025-12-02 | Steven Frank | Director | A | +1,566 | +$11.24K |
| 2025-12-02 | Vincent Milano | Director | A | +783 | +$5.62K |
| 2025-12-02 | Amy E McKee | Director | A | +783 | +$5.62K |
| 2025-11-17 | Machelle Sanders | Director | Sell | −9,600 | −$68.54K |
| 2025-09-03 | Amy E McKee | Director | A | +676 | +$5.62K |
| 2025-09-03 | Vincent Milano | Director | A | +676 | +$5.62K |
| 2025-09-03 | Steven Frank | Director | A | +1,353 | +$11.24K |
| 2025-08-15 | Theresa Heggie | Director | MIXED | — | −$292.17K |
| 2025-07-28 | Babar Ghias | CFO & Head of Corp Development | A | +147,000 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Jon P Stonehouse | Chief Executive Officer | 1,380,419 | $10.70M |
| Charles K Gayer | President and CCO | 892,492 | $6.92M |
| Alane P Barnes | Chief Legal Officer | 463,203 | $3.59M |
| Anthony Doyle | Chief Financial Officer | 380,328 | $2.95M |
| Helen M. Thackray | Chief R&D Officer | 377,318 | $2.92M |
| Babar Ghias | Chief Financial Officer | 268,700 | $2.08M |
| Sandeep Menon | Chief R&D Officer | 205,150 | $1.59M |
| Vincent Milano | Director | 109,642 | $849.73K |
| Nancy J Hutson | Director | 99,138 | $768.32K |
| Steven K Galson | Director | 86,165 | $667.78K |
| Theresa Heggie | Director | 80,646 | $625.01K |
| Alan G Levin | Director | 79,565 | $616.63K |
| Amy E McKee | Director | 47,821 | $370.61K |
| Machelle Sanders | Director | 45,936 | $356.00K |
| Steven Frank | Director | 36,747 | $284.79K |
| Jill C. Milne | Director | 33,226 | $257.50K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BCRX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.